Novartis reports positive long-term Gilenya data
13 June 2012 11:23 in Pharmaceutical Company Product News
Novartis has reported positive data from a long-term extension study of Gilenya, its oral therapy for relapsing forms of multiple sclerosis (MS).
Results from an extension to the phase III head-to-head Transforms study - which compared to the drug to another leading therapy - have shown that Gilenya is able to deliver benefits with up to four-and-a-half years of continuous treatment.
Sustained reduction in relapses and rate of brain volume loss in patients were observed among the Gilenya usage group, while a consistent safety profile was also demonstrated.
As of February 2012, it is estimated that approximately 36,000 patients have been treated using this drug in clinical trials and the post-marketing setting.
Tim Wright, global head of development at Novartis Pharma, said: "This data further reinforces our confidence in Gilenya's long-term effectiveness and safety profile."
Earlier this month, the company published positive clinical data for the investigational compound ACZ885, demonstrating its efficacy against systemic juvenile idiopathic arthritis.
Other news stories from 13/06/2012
Read more in the Zenopa News Archive
How this news is generated
Story collated for Zenopa by the Adfero News Agency